Key result
SGLT2i linked to ~86% fewer CV events in T2D patients on antineoplastic therapy.
Why the study?
Antineoplastic therapies increase cardiorenal toxicity, which is exacerbated by type 2 diabetes mellitus, but the benefits of SGLT2 inhibitors are understudied in T2DM-cancer patients.
Does SGLT2i reduce cardiovascular events and all-cause mortality in T2DM-cancer patients undergoing antineoplastic therapy?
Does SGLT2i reduce cardiovascular events and all-cause mortality in T2DM-cancer patients undergoing antineoplastic therapy?
SGLT2 inhibitors significantly reduce cardiovascular events and all-cause mortality while preserving cardiorenal function in patients with T2DM and cancer undergoing antineoplastic therapy.
May support SGLT2i in T2DM patients on antineoplastic therapy; extends prior CVOT evidence to cardio-oncology but warrants RCTs.
Asia faces a rising cancer burden, with type 2 diabetes mellitus (T2DM) prevalence in cancer patients at 24.4% (2.3‐fold higher than that of the general population). Antineoplastic therapies (e.g., anthracyclines and vascular endothelial growth factor receptor [VEGFR] inhibitors) increase cardiorenal toxicity, exacerbated by T2DM. Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) benefit non‐oncologic populations but are understudied in T2DM–cancer patients. We assessed SGLT2i's effects on antineoplastic‐related cardiorenal toxicity/survival via a multicenter retrospective cohort of 248 T2DM–cancer patients (56.0% male, mean age 66.7 years) 1:1 divided into SGLT2i/non‐SGLT2i groups. Over 30.4 months of follow‐up, SGLT2i reduced cardiovascular events by 86.1% (odds ratio [OR] = 0.139, 95% CI 0.027–0.710, p = .018) and all‐cause mortality by 84.7% (HR = 0.153, 95% CI 0.055–0.431, p < .001). Echocardiography showed improved left ventricular ejection fraction (LVEF) and reduced left ventricular end‐diastolic diameter (LVID)/left atrial (LA) dimensions (all p < .001). Despite lower baseline estimated glomerular filtration rate (eGFR) in the SGLT2i group, SGLT2i preserved renal function (post‐treatment eGFR: 99.8 vs. 67.5 mL/min/1.73 m 2 ; p = .054) and reduced uric acid (UA) levels by 23.6% ( p < .001). Benefits persisted across solid tumor/hematological malignancies and anthracycline‐based therapy, targeted antineoplastic therapy or immunotherapy subgroups, with no increase in infection. SGLT2i improve cardiorenal outcomes and survival in T2DM–cancer patients warranting prospective validation.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question. SGLT2 inhibitors reduced cardiovascular events by 86.1% and all-cause mortality by 84.7% in type 2 diabetes patients undergoing antineoplastic therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: